Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinA

Spasticity Clinical Trial

— RETURN  

Official title:

Retrospective Real-life Study From One Brazilian Reference Centre Assessing Long-term Experience in the Treatment of Adult Spasticity With AbobotulinumtoxinA (RETURN Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04446702
• Other study ID #: A-BR-52120-269
• Status: Completed
• Start date: March 5, 2021
• Est. completion date: December 10, 2021

Study information

• Verified date: December 2021
• Source: Ipsen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the study is to describe the long-term use of abobotulinumtoxinA (Dysport®) in adult subjects affected with upper limb spasticity (ULS) +/- lower limb spasticity (LLS) who received treatment with Dysport® for a minimum of three injections cycles at the Instituto de Medicina Física e Reabilitação do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IMREA HC FMUSP) in Brazil.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: December 10, 2021
• Est. primary completion date: December 10, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult aged =18 years old at the time of the first Dysport® injection
• Diagnosed with spasticity
• Treated with a minimum of three Dysport® injection cycles for ULS +/- LLS in the observational period
• Follow up effectiveness data are available in the subject's medical record

Exclusion Criteria:

• Patients have received previous treatment with another BoNT-A less than 12 weeks prior to the patient data collection in the study
• Adults with cerebral palsy
• Patients treated with BoNT-A in a clinical trial setting

Related Conditions & MeSH terms

• Muscle Spasticity
• Spasticity

Locations

Country	Name	City	State
Brazil	Instituto de Medicina Física e Reabilitação do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IMREA HC FMUSP)	San Paolo

Sponsors (1)

Lead Sponsor	Collaborator
Ipsen

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average total dose injected during all sessions of Dysport® in ULS +/- LLS		From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Primary	Median total dose injected during all sessions of Dysport® in ULS +/- LLS		From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Primary	Average interval between Dysport® injections in ULS +/- LLS		From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Baseline subjects characteristics	Demography (age at first injection during the period of interest, sex, weight); History of spasticity	Baseline (first Dysport® injection)
Secondary	Total number of Dysport® injection cycles		From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Total time exposure to Dysport® treatment in ULS +/- LLS		From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Total dose injected per cycle, per limb, per muscle and overall		From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Number of muscles injected in ULS +/- LLS		From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Reported reason for Dysport® injection and for change	Outcome will be assessed according following reasons: due to medical need, unplanned need and not recorded	From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Number of Dysport® interruptions		From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Reasons of Dysport® discontinuation	Outcome will be assessed according following reasons: side effects (e.g. excessive weakness, hematoma), contractures, absence of clinical response, long lasting clinical improvement, patient lost follow up and other.	From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019).
Secondary	Changes in Modified Ashworth Scale (MAS) scores by time period per muscle	The MAS is a six-point scale to grade muscle tone in the injected muscle from 0 (no increase in tone) to 4 (affected parts rigid in flexion or extension). Upper limb: shoulder abduction, elbow flexion, elbow extension, wrist flexion, wrist extension and fingers flexion. Lower limb: hip flexion, hip adduction, hip abduction, knee flexion, knee extension, ankle dorsiflexion and ankle plantar flexion.	From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Changes in Functional Independence Measure (FIM) subscales	Subscales and total scores of FIM will be measured. The FIM is a method for categorising patients on a seven-point scale (range 1 to 7). It comprises of 18 items, grouped into 2 subscales (motor and cognition). The motor subscale includes: eating, grooming, bathing, dressing upper body, dressing lower body, toileting, bladder management, bowel management, transfers - bed/chair/wheelchair, transfers - toilet, transfers - bath/shower, walk/wheelchair and stairs. The cognition subscale includes: comprehension, expression, social interaction, problem solving and memory. The Scores are summed to obtain a total score that can range between 18 and 126.	From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Changes in Pain score according to pain Visual Analogue Scales (VAS)	The pain Visual Analogue Scale (VAS) is a numeric graphic rating scale (NGRS) of self-reported symptoms. Scores are recorded as whole numbers between zero and 10, where zero indicates no pain symptom at all, and 10 indicates a as bad as it could be.	From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Gait pattern evaluation in patients with LLS	Gait Pattern Modification in patients with LLS is based on physician´s clinical evaluation and it will be evaluated for each lower limb (left and right) or both according to pre-specified patterns: equinismus, foot inversion, knee hyperextension, adduction, mowing abduction, thigh elevation, hip elevation, false trendelenburg, not able to walk. The Gait Pattern Improvement is described based on patient´s perception of gait. The patients respond Yes or No and if Yes the % of improvement is replied	From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Concomitant drugs for the management of patients with ULS +/- LLS	List the systemic drug therapies, including: antispasticity medications (e.g. Baclofen, Tizanidin, Dantrolene), simple pain medications (e.g. paracetamol or NSAIDS), neuropathic pain and spasticity medications (e.g. Gabapentin, Pregabalin, Amitriptyline), opioids, phenol, alcool or other neurolytic agents.	From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Non-drug concomitant therapies for the management of patients with ULS +/- LLS	List the non-drug concomitant therapies, including occupational therapy, physiotherapy and others (e.g.: orthotics, serial casting, splinting, electric stimulation)	From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Secondary	Incidence and intensity of Adverse Events	Adverse events will be assessed according to incidence, intensity/grade (mild, moderate and severe), causality (related and not related to the product), outcome (the overall association between an exposure to a drug and an outcome) and action taken. All Adverse Events (AEs) (including fatal events and Serious Adverse Events (SAEs)) and special situation (pregnancy, overdose, off-label use) will be reported with the number and proportion of events. The incidence will be provided and classified by System Organ Class and Preferred Term	From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)